BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer

 BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer

BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer

Shots:

  • The first patient has been dosed in global P-III AdvanTIG-302 trial evaluating ociperlimab + tislelizumab in 605 naïve patients with locally advanced, unresectable, or metastatic NSCLC whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations across the US, Australia & other countries globally
  • The 1EPs of the trial are PFS & OS in the ITT population & 2EPs include safety and other efficacy EPs
  • Ociperlimab is currently being investigated in combination with tislelizumab in multiple ongoing trials while the company plans to explore the potential use of ociperlimab in additional settings & indications in its late-stage development program

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post